Keeping Track: Axsome’s Auvelity Survives Long Review; Bluebird’s Zynteglo Cleared For Liftoff; Omeros Appeals CRL

 
• By Bridget Silverman
Keeping Track Feature image
Latest FDA approvals include Auvelity, a rapid-acting oral treatment for depressive symptoms.

More from US FDA Performance Tracker

More from Regulatory Trackers